# US 10,441,644 B2 · H3.3 CTL peptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,644 B2
- Document ID: US10441644B2
- Status: Granted
- Kind: B2
- Application number: 15/613,837
- Filed: 2017-06-05
- Published: 2017-10-05
- Granted: 2019-10-15
- Earliest claimed: 2015-05-05
- Assignees: The Regents of the University of California
- Applicants: Regents of the University of California
- Inventors: Hideho Okada; Yafei Hou
- Web page: https://patentgrep.com/patent/US10441644B2

## CPC

- G01N 33/505: {involving T-cells}
- A61K 38/03: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- C07K 14/47: from mammals
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- G01N 33/5014: {for testing toxicity}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/47: Brain; Nervous system
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

## Claims

### Claim 1

A T-cell expressing one or more polypeptides comprising a T-cell receptor (TCR) or fragment thereof that binds to a peptide/major histocompatibility complex (MHC) complex, wherein the peptide in the peptide/MHC complex consists of 10-12 amino acids and comprises (R/A)MSAP(S/A)TGGV (SEQ ID NO:1).

### Claim 2 (depends on 1)

The T-cell of claim 1, wherein the TCR or fragment thereof is heterologous to the T-cell.

### Claim 3 (depends on 1)

The T-cell of claim 1, wherein expression of the TCR or fragment thereof is under the control of a heterologous promoter.

### Claim 4 (depends on 1)

The T-cell of claim 1, wherein the peptide consists of RMSAPSTGGV (SEQ ID NO:2).